CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced its financial results and business highlights for the first-quarter of 2013. Highlights
- Aegerion has more than 185 U.S. commercial and global named patient prescriptions for JUXTAPID written, and 75 patients are currently on JUXTAPID therapy. Re-orders for patients are on track and dropouts to date have been minimal.
- A significant foundation of REMS-trained physicians is established and growing.
- The company participated in a Scientific Advisory Group meeting at the European Medicines Agency (EMA) on April 9 th.